Status:
TERMINATED
Imaging of CB1 Receptors Using (11C)SD5024
Lead Sponsor:
National Institute of Mental Health (NIMH)
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Background: \- The cannabinoid type 1 (CB1) receptor is a protein found on some brain cells. It may play a role in obesity or some psychiatric disorders such as schizophrenia. Imaging studies like po...
Detailed Description
The cannabinoid type 1 (CB(1)) receptor is one of the most abundant G protein-coupled receptors in the brain (Matsuda et al 1990). It is found on glutamatergic, dopaminergic, and gamma aminobutyric ac...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Healthy control subjects aged 18 50 whose medical history, physical exam, electrocardiogram (ECG), and laboratory test results are within normal limits within one year of the PET scan will be eligible to participate.
- EXCLUSION CRITERIA:
- Any recent or past history of psychiatric illness or severe systemic disease based on history and physical exam.
- Serious medical illness likely to modify brain anatomy and/or physiology (head trauma, past brain surgery, neurological disorders such as epilepsy, Parkinson disease, and psychiatric disorders such as schizophrenia and depression)
- Any current substance or alcohol abuse, with the exception of nicotine.
- Positive urine toxicology screen
- Radiation exposure from participation in other research protocols in the last year such that the additional radiation exposure from this protocol would exceed annual limits.
- Pregnant or breastfeeding.
- Claustrophobia (applies to Parts 1 and 3 only).
- Metallic (ferromagnetic) implants, including pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pump, shrapnel fragments, and possible small metal fragments in the eye (applies to Parts 1 and 3 only).
- Unable to lie flat on back for up to 2.5 hours.
Exclusion
Key Trial Info
Start Date :
June 22 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2013
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT01399398
Start Date
June 22 2011
End Date
December 18 2013
Last Update
November 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892